Reporte zur Charge 5N6199

Symptomtext

Second dose: was sick; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient. A 70 year-old female patient received bnt162b2 (BNT162B2), administered in arm left, administration date 07Mar2021 (Lot number: 5N6199) at the age of 70 years as dose 2, single for covid-19 immunisation. Relevant medical history included: "Hypersensitivity" (unspecified if ongoing), notes: Verbatim: Allergy, body is severely sensitive; "she has had swollen eyes from being in a lumber store" (unspecified if ongoing); "can smell chemicals a mile away" (unspecified if ongoing); "had a rash from latex and metal" (unspecified if ongoing); "had a rash from latex and metal" (unspecified if ongoing); "had a reaction to cats" (unspecified if ongoing); "had a reaction to yellow flowers" (unspecified if ongoing); "had a reaction to Hay" (unspecified if ongoing). Concomitant medication(s) included: COZAAR; IBUPROFEN. Past drug history included: Amoxicillin, reaction(s): "gets a rash". Vaccination history included: Bnt162b2 (First Dose: Received 17Feb2021, lot EM1809 or EM7809, NDC and expiration date unknown.), administration date: 17Feb2021, when the patient was 70 years old, for COVID-19 immunization, reaction(s): "didn't feel great after the first dose"; Tetanus shot, administration date: 2020, reaction(s): "little reaction". The following information was reported: ILLNESS (non-serious) with onset 2021, outcome "unknown", described as "Second dose: was sick". The patient underwent the following laboratory tests and procedures: full blood count normal: perfectly normal; haematocrit: perfectly normal; hormone level abnormal: unknown, notes: it was really different. Additional information: The reporter stated that the event relatedness as related. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient id not receive any recent vaccines for SARS-CoV2 other than Pfizer-BioNTech COVID-19 Vaccine prior to the event being reported. Follow-up attempts are completed. No further information is expected.